Pharmabiz11m
DFE Pharma expands its C2F Center of Excellence in Hyderabad to advance the development of critical respiratory treatments
DFE Pharma, a global leader in pharmaceutical and biopharmaceutical excipient solutions, has expanded the capabilities of its Closer to the Formulator (C2F) Center of Excellence located in Genome ...
Pharmabiz1h
PDMA asks govt to create separate category for units below Rs. 10 crore & allow 3 years to implement revised Schedule M
Gireesh Babu, New Delhi Tuesday, January 14, 2025, 08:00 Hrs [IST] ...
Pharmabiz1h
Pharmacy Council of India fixes staff to students ratio for B.Pharm as 1:20
The Pharmacy Council of India (PCI) has stipulated that the staff to student ratio for Bachelor of Pharmacy (B.Pharm) courses should not exceed 1:20 in theory classes and practical classes. The ...
Pharmabiz1h
HPMA demands three years’ time for full compliance with revised Schedule M
HPMA demands three years’ time for full compliance with revised Schedule M: Peethaambaran Kunnathoor, Chennai Tuesday, ...
Pharmabiz1h
India initiates anti-dumping probe on Resorcinol imports from China and Japan
India initiates anti-dumping probe on Resorcinol imports from China and Japan: Shardul Nautiyal, Mumbai Tuesday, January 14, 2025, 08:00 Hrs [IST] The Directorate General of Trade ...
Pharmabiz6d
CDSCO establishes Sub-Zonal Office in Bhubaneswar, boosting Odisha’s pharmaceutical sector
In a significant move to enhance drug regulation and monitoring in Odisha, the Central Drugs Standard Control Organisation (CDSCO) has announced the establishment of a Sub-Zonal Office in Bhubaneswar.
Pharmabiz6d
Indian healthcare sees medical networking as catalyst for quality services in remote regions
The Indian healthcare sector sees emergence of medical networking to revolutionise quality services in remote regions. This is despite the resource and infrastructural constraints leading to the ...
Pharmabiz10d
Centre notifies amendments to Foreign Trade Policy 2023 to enhance stakeholder engagement
The Union ministry of commerce & industry has issued a notification introducing amendments to the Foreign Trade Policy (FTP) 2023, aimed at fostering enhanced stakeholder engagement. The notification, ...
Pharmabiz6d
Santhera enters supply and distribution agreement with Clinigen Group for Agamree to treat patients with Duchenne muscular dystrophy
Santhera Pharmaceuticals announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of Agamree (vamorolone) in countries where the product is not ...
Pharmabiz6d
JCR Pharma & Modalis validate initial proof of concept in a joint research programme for development of a novel gene therapy for a CNS disease
JCR Pharmaceuticals Co., Ltd., a global specialty pharmaceuticals company, and Modalis Therapeutics Corporation, a forerunner in the field of epigenetic medicine, announced that they have validated ...
Pharmabiz7d
Eton Pharma acquires Galzin, an US FDA approved treatment of ultra-rare metabolic condition of Wilson disease
Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced that it has acquired Galzin (zinc acetate). “This ...
Pharmabiz6d
US FDA grants orphan drug designation to NMD Pharma’s NMD670 to treat patients with Charcot-Marie-tooth disease
NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, announces that the US Food and Drug ...